Global Pharmatech, Inc. a company that develops, manufactures and markets proprietary botanical drugs and dietary supplements, today announced that the State Intellectual Property Office of the P. R. China has recently granted new patents to two drug candidates, Shenxiangsuhe Pills (patent number: ZL200410010947.7) and Xinshu Pills (patent number: ZL200410011088.3) to Natural Pharmatech (Jilin), a wholly owned subsidiary of Global Pharmatech, Inc.
Dr. Xiaobo Sun, President and CEO of Global Pharmatech stated: ''Our company is developing these two drug candidates for the treatment of coronary diseases, including angina pectoris. We are very pleased to have patent protection for these drug candidates in our pipeline. The incidence of coronary diseases has been gradually increased in China during the past two decades. These two patents will protect our proprietary technologies and enable us to develop better herbal drugs for the treatment of cardiovascular diseases in China. Based on available data we have obtained, we have confidence to bring these two products onto Chinese market with the next two to three years.''
About Global Pharmatech
Global Pharmatech, through its subsidiaries, develops, manufactures and markets proprietary drugs that are based on Traditional Chinese Medicine using modern facilities and advanced R&D technologies. The company offers a full range of start-to-finish biotech services, from research and testing to manufacture and sale of liquid and solid dose products. The Company employs unique proprietary extraction methods and also licenses patents and technologies for botanical/biological drug products. Global Pharamtech's operations are currently based in the People's Republic of China with sales distribution centers in China, Malaysia, Singapore and Indonesia. For more information, please visit Global Pharmatech.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements within the meaning of the ''safe harbour'' provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to successfully develop and commercialize products, competitive products in our key markets, changes in consumer demand for our products, legislative, regulatory and competitive developments and general economic conditions. Our SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.